Klaus Bosslet
44Patents
16h-index
53Co-inventors
80Inventor score
Filing activity: May 27, 1994 → Feb 7, 2008
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5591828A | Bispecific and oligospecific mono-and oligovalent receptors, the preparation and use thereof | Human Necessities | 411 | Expired |
| US5959083A | Tetravalent bispecific receptors, the preparation and use thereof | Emerging Cross-Sectional Technologies | 168 | Expired |
| US5830880A | Gene therapy of tumors with an endothelial cell-specific, cell cycle-dependent active compound | Chemistry; Metallurgy | 146 | Expired |
| US5621002A | Prodrugs for enzyme mediated activation | Performing Operations; Transporting | 103 | Expired |
| US5561119A | Glycosylated prodrugs, their method of preparation and their uses | Chemistry; Metallurgy | 61 | Expired |
| US5955100A | Prodrugs their preparation and use as pharmaceuticals | Emerging Cross-Sectional Technologies | 51 | Expired |
| US7129254B2 | Effector conjugates, process for their production and their pharmaceutical use | Chemistry; Metallurgy | 41 | Expired |
| US6241961A | Radioimmuno conjugates for use in human therapy and method for their preparation | Performing Operations; Transporting | 28 | Expired |
| US6146658A | Prodrugs, their preparation and use as pharmaceuticals | Emerging Cross-Sectional Technologies | 28 | Expired |
| US5935995A | Prodrugs for the therapy of tumors and inflammatory disorders | Human Necessities | 26 | Expired |
| US5877158A | Pro-prodrugs, their production and use | Performing Operations; Transporting | 25 | Expired |
| US7060495B2 | Fusion proteins for prodrug activation | Chemistry; Metallurgy | 23 | Expired |
| US6548067B1 | Antigenic constructs of major histocompatibility complex class I antigens with specific carrier molecules, the preparation and use thereof | Chemistry; Metallurgy | 23 | Expired |
| US6020315A | Preparation having increased in vivo tolerability | Human Necessities | 20 | Expired |
| US5710134A | Combination of necrosis-inducing substances with substances which are activated by necroses for the selective therapy of tumors and inflammatory disorders | Human Necessities | 19 | Expired |
| US6602688B1 | Cytoplasmic expression of antibodies, antibody fragments and antibody fragment fusion proteins in E. coli | Emerging Cross-Sectional Technologies | 18 | Expired |
| US6926896B2 | Monoclonal antibodies (MAbs) against tumor-associated antigens, the preparation and use thereof | Chemistry; Metallurgy | 13 | Expired |
| US6294172A | Monoclonal antibodies with specificity for membrane-associated antigens | Human Necessities | 11 | Expired |
| US6008023A | Cytoplasmic expression of antibodies, antibody fragments and antibody fragment fusion proteins in E. coli | Emerging Cross-Sectional Technologies | 10 | Expired |
| US6610299B1 | Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates | Chemistry; Metallurgy | 9 | Expired |
| US5643731A | Use of pairs of leucine zipper peptides in immunoassay methods | Emerging Cross-Sectional Technologies | 6 | Expired |
| US5639622A | Monoclonal antibodies against tumor-associated antigens, a process for the preparation thereof and the use thereof | Human Necessities | 5 | Expired |
| US5686583A | Specific antibodies against activated platelets, the preparation thereof and the use thereof in diagnosis and therapy | Chemistry; Metallurgy | 5 | Expired |
| US5639621A | Monoclonal antibodies against tumor-associated antigens | Chemistry; Metallurgy | 4 | Expired |
| US5645817A | Granulocyte-binding antibody constructs, their preparation and use | Chemistry; Metallurgy | 4 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.